LUMAKRAS
Analogs of LUMAKRAS
Find cheaper analogs and generic equivalents for LUMAKRAS.
Active Ingredient: SOTORASIB
Product Overview
About LUMAKRAS
LUMAKRAS is a prescription medication containing the active ingredient Sotorasib, a selective and irreversible inhibitor of KRAS G12C mutations. It is used in the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation, as detected by an FDA-approved test.
Key Benefits & Uses
- Treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation
- Used in combination with other treatments for NSCLC, as determined by your healthcare provider
- Administered orally, once daily, in a 960 mg dose
Active Ingredient & Action
Sotorasib works by selectively binding to the KRAS G12C mutation, inhibiting the activity of the KRAS protein and blocking the downstream signaling pathways that promote cancer cell growth and survival. This leads to a reduction in tumor size and an improvement in symptoms.
Important Notes
Before taking LUMAKRAS, inform your healthcare provider about all your medical conditions, including liver or kidney problems. LUMAKRAS may cause serious side effects, including liver damage, diarrhea, and infusion reactions. Your healthcare provider will monitor your liver function and adjust your treatment as needed. It is essential to follow the recommended dosage and administration instructions to minimize the risk of adverse effects.
Visitor ratings
Help others by rating how useful this product page is.
No ratings yet — be the first.